| Market Capitalization (Millions $) |
927 |
| Shares
Outstanding (Millions) |
20 |
| Employees |
174 |
| Revenues (TTM) (Millions $) |
277 |
| Net Income (TTM) (Millions $) |
322 |
| Cash Flow (TTM) (Millions $) |
-29 |
| Capital Exp. (TTM) (Millions $) |
70 |
Business Description
Rigel Pharmaceuticals Inc. is a biotechnology company that is based in South San Francisco, California. It is a publicly-traded company that is listed on the NASDAQ stock exchange under the ticker symbol RIGL. The company specializes in the research and development of novel drugs for the treatment of several diseases such as thrombocytopenia, immune diseases, and cancer, among others.
Rigel Pharmaceuticals was founded in 1996 and has been a pioneer in the development of therapies for immune diseases. The company's primary focus is on the discovery, design, and development of small molecule drugs that can modulate signaling pathways that regulate immune function. Rigel's drug candidates target the signaling pathways associated with the T-cell receptor, B-cell receptor, and chemokine receptors.
The company has a robust drug discovery platform that is built upon its deep understanding of the biology of the immune system. Rigel's scientists utilize a combination of technologies such as high-throughput screening, medicinal chemistry, and structural biology to identify and optimize drug candidates. The company has a strong intellectual property portfolio that includes patents and patent applications covering its drug candidates.
Rigel Pharmaceuticals has several drug candidates in clinical development. Its lead product candidate, fostamatinib disodium (Tavalisse), has been approved by the US FDA for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Fostamatinib is a spleen tyrosine kinase (SYK) inhibitor that can modulate the immune response.
In addition to fostamatinib, Rigel has several other drug candidates in clinical development. These include R835 (a dual spleen tyrosine kinase and Janus kinase (JAK) inhibitor) for the treatment of autoimmune diseases such as rheumatoid arthritis, and R552 (an inhibitor of receptor activator of nuclear factor kappa-B ligand (RANKL)) for the treatment of osteoporosis.
Rigel Pharmaceuticals has partnerships with several pharmaceutical companies to develop and commercialize its drug candidates. These include AstraZeneca for fostamatinib and BerGenBio for a cancer drug candidate. The company has also received funding from government agencies such as the National Institutes of Health and the Defense Advanced Research Projects Agency.
In conclusion, Rigel Pharmaceuticals is a biotechnology company that focuses on the discovery and development of drugs for the treatment of immune diseases, cancer, and other conditions. The company has a strong drug discovery platform based on its deep understanding of the immune system, and it has a pipeline of drug candidates in clinical development. With several partnerships and a strong intellectual property portfolio, Rigel is poised for continued growth in the biopharmaceutical industry.
Company Address: 611 Gateway Boulevard, Suite 900, South San Francisco 94080 CA
Company Phone Number: 624-1100 Stock Exchange / Ticker: NASDAQ RIGL
|
4.37% 
154.93 %